Roche confirmed its profit outlook for the year after its eye drug Vabysmo, multiple-sclerosis treatment Ocrevus and hemophilia injection Hemlibra lifted third-quarter sales above analysts ...

Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple sclerosis drug Ocrevus. Jefferies said it downgraded the stock on three ...

This article discusses pregnancy and breastfeeding information related to Ocrevus. To learn more about Ocrevus that’s unrelated to pregnancy and breastfeeding, see this article.

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability ...

Roche's quarterly sales declined 6% as a slump in COVID-19 treatments and diagnostic testing outweighed gains from haemophilia treatment Hemlibra and multiple sclerosis drug Ocrevus.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has its own injectable MS drug, Kesimpta.

Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said on Wednesday.

How Does Ocrevus’ Market Share Gains Impact Roche’s Earnings & Price Estimate? If Ocrevus manages to double its share in the multiple sclerosis market, it will result in $0.27 incremental ...

DUBLIN-- (BUSINESS WIRE)--The "Drug Analysis: Ocrevus" drug pipelines has been added to ResearchAndMarkets.com's offering. Ocrevus is a second-generation cluster of differentiation (CD)20 antibody ...

Roche has announced positive results from a late-stage study of Ocrevus (ocrelizumab) as a twice-yearly subcutaneous injection in patients with relapsing forms of multiple sclerosis (MS) or primary ...

Roche Holdings (RHHBY) announced positive analyses from three phase III studies on its multiple sclerosis candidate, Ocrevus.